BAYER

BAYER

Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU

A New Hope for Prostate Cancer Patients In a significant development for prostate cancer treatment, Bayer has announced the submission of an application to the European Medicines Agency (EMA) for the oral androgen receptor inhibitor (ARi) darolutamide..

BAYER

Bayer applies for EU approval of menopause drug elinzanetant

Bayer, one of the world’s leading pharmaceutical companies, has made a significant move in the treatment of menopausal symptoms by submitting a marketing authorization application to the European Medi..